Trial Profile
A Multi-Center, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Apr 2023
Price :
$35
*
At a glance
- Drugs Edaravone (Primary)
- Indications Amyotrophic lateral sclerosis; Cerebral infarction; Liver disorders; Stroke
- Focus Pharmacokinetics
- Sponsors Mitsubishi Tanabe Pharma America
- 13 Aug 2020 Results published in the Clinical Therapeutics
- 26 Nov 2018 Status changed from recruiting to completed.
- 22 Sep 2017 New trial record